The role of perfusion and the development of surrogate measurements to enable high density T cell cu

• 作 者: Stephen Minger
• 机 构: Global Director for R&D for Cell Technologies at GE Healthcare
• 出 处: 第十四届全国肿瘤生物治疗大会
• 发表日期: 2015年期

　　Scalable, high quality cell manufacturing is key to providing safe, effective and economically viable cell therapies.In the case of autologous T-cell therapies this entails, high density expansion of cells in robust closed and automatable systems.